A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia) for Crohn's Disease
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 03 Oct 2017
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Crohn's disease
- Focus Adverse reactions
- Acronyms SECURE
- Sponsors UCB
- 28 Sep 2017 Planned End Date changed from 1 Jan 2029 to 1 Aug 2025.
- 28 Sep 2017 Planned primary completion date changed from 1 Dec 2028 to 1 Aug 2025.
- 28 Sep 2017 Status changed from recruiting to active, no longer recruiting.